Current and historical daily PE Ratio for CGEM (
Cullinan Therapeutics Inc
) from 2021 to May 18 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Cullinan Therapeutics stock (CGEM) PE ratio as of May 18 2024 is 0.
More Details
Cullinan Therapeutics Inc (CGEM) PE Ratio (TTM) Chart
Cullinan Therapeutics Inc (CGEM) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 846
- 1
- 2
- 3
- 4
- 5
- 6
- 10
| Cullinan Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-18 | At Loss | 2024-03-15 | At Loss |
| 2024-05-17 | At Loss | 2024-03-14 | At Loss |
| 2024-05-16 | At Loss | 2024-03-13 | At Loss |
| 2024-05-15 | At Loss | 2024-03-12 | At Loss |
| 2024-05-14 | At Loss | 2024-03-11 | At Loss |
| 2024-05-13 | At Loss | 2024-03-08 | At Loss |
| 2024-05-10 | At Loss | 2024-03-07 | At Loss |
| 2024-05-09 | At Loss | 2024-03-06 | At Loss |
| 2024-05-08 | At Loss | 2024-03-05 | At Loss |
| 2024-05-07 | At Loss | 2024-03-04 | At Loss |
| 2024-05-06 | At Loss | 2024-03-01 | At Loss |
| 2024-05-03 | At Loss | 2024-02-29 | At Loss |
| 2024-05-02 | At Loss | 2024-02-28 | At Loss |
| 2024-05-01 | At Loss | 2024-02-27 | At Loss |
| 2024-04-30 | At Loss | 2024-02-26 | At Loss |
| 2024-04-29 | At Loss | 2024-02-23 | At Loss |
| 2024-04-26 | At Loss | 2024-02-22 | At Loss |
| 2024-04-25 | At Loss | 2024-02-21 | At Loss |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-04-01 | At Loss | 2024-01-25 | At Loss |
| 2024-03-28 | At Loss | 2024-01-24 | At Loss |
| 2024-03-27 | At Loss | 2024-01-23 | At Loss |
| 2024-03-26 | At Loss | 2024-01-22 | At Loss |
| 2024-03-25 | At Loss | 2024-01-19 | At Loss |
| 2024-03-22 | At Loss | 2024-01-18 | At Loss |
| 2024-03-21 | At Loss | 2024-01-17 | At Loss |
| 2024-03-20 | At Loss | 2024-01-16 | At Loss |
| 2024-03-19 | At Loss | 2024-01-12 | At Loss |
| 2024-03-18 | At Loss | 2024-01-11 | At Loss |
Cullinan Therapeutics Inc (CGEM) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Cullinan Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US2300311063
Share Class Description:
CGEM: Ordinary SharesDescription
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers